SCHEMBL17491483

SCHEMBL17491483

CC1(C)CC1C(=O)Nc1cc(-c2cnco2)cc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHOA P61586 1/20 0.46
▸ IMPDH2 P12268 5/20 0.39
▸ IMPDH1 P20839 4/20 0.39
▸ KDR P35968 3/20 0.39
▸ EGFR P00533 2/20 0.39
▸ FGFR1 P11362 2/20 0.39
▸ DYRK1A Q13627 6/20 0.39
▸ GSK3B P49841 4/20 0.39
▸ WNT1 P04628 3/20 0.39
▸ CLK2 P49760 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ AAK1 Q2M2I8 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491474 0.85 RHOA (0.50) RHOAIMPDH2IMPDH1KDREGFR
SCHEMBL17491438 0.84 RHOA (0.55) RHOAKDREGFRFGFR1DYRK1A
SCHEMBL17491403 0.83 RHOA (0.58) RHOADYRK1AGSK3BWNT1CLK2
SCHEMBL17491529 0.83 RHOA (0.58) RHOADYRK1AGSK3BWNT1CLK2
SCHEMBL17491442 0.83 RHOA (0.51) RHOAIMPDH2IMPDH1KDREGFR
SCHEMBL17491445 0.83 TEK (0.42) RHOAIMPDH2IMPDH1KDREGFR
SCHEMBL17491415 0.82 BRAF (0.47) RHOAIMPDH2IMPDH1KDREGFR
SCHEMBL17491506 0.82 RHOA (0.60) RHOADYRK1AGSK3BWNT1CLK2
SCHEMBL17491522 0.82 DYRK1A (0.53) RHOAKDREGFRFGFR1DYRK1A
SCHEMBL17491534 0.79 TEK (0.42) RHOAIMPDH2IMPDH1KDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 RHOA 2405/4885IMPDH2 1603/4885IMPDH1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback